Lysosomal Storage Disease Overview

Principles

Definition

Lysosomal storage disease is an academic concept and research field focusing on a class of rare inherited metabolic disorders characterized by deficient lysosomal function, resulting in the pathological accumulation of specific substrates within cells. This area investigates the molecular mechanisms, clinical manifestations, diagnosis, and therapeutic interventions for these conditions, representing a significant area of study in genetics, cell biology, and medical science.

Ontological type

Therapeutic Strategies

Genetic Basis

Diagnostic Approaches

Key developments

Key Figures

Enzymatic Diagnostics Paradigm era

Christian de Duve, whose discovery and characterization of lysosomes in the 1950s and 1960s established the cellular basis for lysosomal storage diseases, provided the conceptual framework for enzymatic diagnostics. Roscoe Brady and his colleagues, active through the 1960s and 1970s, advanced the paradigm by developing quantitative assays of lysosomal hydrolases and applying them to Gaucher disease, Niemann-Pick and related storage disorders. Their work operationalized small-sample enzyme testing, purification protocols, and substrate assays into reproducible diagnostic pipelines that translated biochemical defects into clinical phenotypes. Together, de Duve's lysosome-centric biology and Brady's diagnostic enzymology catalyzed a biomarker-driven era that shaped subsequent mechanistic studies and therapeutic development.

Lysosomal Trafficking Mechanisms era

Robert J. Desnick[1] emerged as a leading figure in the Lysosomal Trafficking Mechanisms era (1980-2002) with affiliations at Harvard University[3] and Stanford University[4]. His Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency[6] demonstrated that defects in lysosomal enzymes can drive disease, underscoring the central role of trafficking and localization in lysosomal pathogenesis during this era. Ira Pastan[2] is a prominent figure in this era with affiliations at Harvard University[3] and La Roche College[5]. His Identification of two lysosomal membrane glycoproteins[7] revealed key components of lysosomal membranes and informed understanding of trafficking routes that govern hydrolase targeting in this era.

Lysosome Homeostasis and Therapy era

Fabio Ciceri [1] emerges as a leading figure in the Lysosome Homeostasis and Therapy era, with affiliations at San Raffaele University of Rome [3] and Université Paris Cité [4]. His key contribution in this era is involvement in the lentiviral hematopoietic stem cell gene therapy for metachromatic leukodystrophy [6], a strategy that enables durable systemic enzyme delivery and autologous correction, aligning with organelle-centered approaches to lysosomal storage diseases. Luigi Naldini [2] is associated with Forest Institute [5] and San Raffaele University of Rome [3], reflecting his role across institutions shaping gene therapy in this era. His contributions center on refining lentiviral vector–based hematopoietic stem cell gene therapy for metachromatic leukodystrophy [6], informing translational strategies to restore lysosomal function and organelle homeostasis in neurodegenerative lysosomal storage diseases.